Scilex Holding Company (SCLX)
NASDAQ: SCLX · IEX Real-Time Price · USD
1.930
+0.050 (2.66%)
At close: Jul 2, 2024, 4:00 PM
2.570
+0.640 (33.16%)
After-hours: Jul 2, 2024, 7:59 PM EDT
Scilex Holding Company Revenue
Scilex Holding Company had revenue of $47.05M in the twelve months ending March 31, 2024, with 12.54% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $10.88M with 2.85% year-over-year growth. In the year 2023, Scilex Holding Company had annual revenue of $46.74M with 22.90% growth.
Revenue (ttm)
$47.05M
Revenue Growth
+12.54%
P/S Ratio
7.43
Revenue / Employee
$443,821
Employees
106
Market Cap
349.70M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 46.74M | 8.71M | 22.90% |
| Dec 31, 2022 | 38.03M | 6.72M | 21.45% |
| Dec 31, 2021 | 31.32M | 7.76M | 32.92% |
| Dec 31, 2020 | 23.56M | 2.53M | 12.01% |
| Dec 31, 2019 | 21.03M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bioventus | 522.74M |
| Organogenesis Holdings | 435.47M |
| Health Catalyst | 296.79M |
| Talkspace | 162.13M |
| Agenus | 161.42M |
| ADC Therapeutics | 68.62M |
SCLX News
- 6 hours ago - Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination - GlobeNewsWire
- 14 hours ago - Scilex Holding Company to Ring Nasdaq Closing Bell on Friday, July 5th at 4:00PM ET at the Nasdaq MarketSite in Times Square, New York - GlobeNewsWire
- 12 days ago - Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC. - GlobeNewsWire
- 18 days ago - Scilex Holding Company Announces Publication in PAIN Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (SEMDEXA™) in Lumbosacral Radicular Pain (Sciatica) - GlobeNewsWire
- 21 days ago - Scilex Holding Company Announces 5-Year Term of $100 Million Financing with Royalty-Based Payments and Potential Strategic Transactions with Perigrove and its Portfolio Companies - GlobeNewsWire
- 21 days ago - Scilex Holding Company Announces That Many National Pharmacy Chains and Independent Pharmacies Have Begun Stocking GLOPERBA® - GlobeNewsWire
- 22 days ago - Scilex Holding Company Announces Stocking of GLOPERBA® is Underway in all of the Wholesalers with which Scilex has Stocking Arrangements Throughout the U.S. - GlobeNewsWire
- 26 days ago - Scilex Holding Company announces the U.S. FDA has approved the sNDA for commercial manufacturing of Gloperba® which will be launched in the US in the week of June 10th 2024 - GlobeNewsWire